CoChat

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection

Open access
Tio, Martin, Rai, Rajat, Ezeoke, Ogochukwu M., McQuade, Jennifer L., Zimmer, Lisa, Khoo, Chloe, Park, John J., Spain, Lavinia, Turajlic, Samra, Ardolino, Luke, Yip, Desmond, Goldinger, Simone M., Cohen, Justine V., Millward, Michael, Atkinson, Victoria, Kane, Alisa Y., Ascierto, Paolo A., Garbe, Claus, Gutzmer, Ralf, Johnson, Douglas B., Rizvi, Hira A., Joshua, Anthony M., Hellmann, Matthew D., Long, Georgina V., Menzies, Alexander M. · 2018 · European Journal of Cancer
Cited by 129

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Background: Anti-programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) immunotherapy is now routinely used to treat several cancers. Clinical trials have excluded several populations, including patients with solid organ transplant, HIV infection and hepatitis B/C infection. We examined the safety outcomes of these populations treated with anti-PD-1/PD-L1 treatment in a multicentre retrospective study. Methods: Patients from 16 centres with advanced cancer and solid organ transplant, HIV infection or hepatitis B/C infection were included. Demographic, tumour, treatment, toxicity and outcome data were recorded. Results: Forty-six patients were included for analysis, with a median age of 60 years, and the majority of patients diagnosed with melanoma (72%). Among six patients with solid organ transplants, two graft rejections occurred, with one resulting in death, whereas two patients achieved partial responses. There were four responses in 12 patients with HIV infection. In 14 patients with hepatitis B, there were three responses, and similarly, there were three responses in 14 patients with hepatitis C. There was no unexpected toxicity in any viral infection group or an increase in viral load. Conclusion: Patients with HIV or hepatitis B/C infections treated with anti-PD-1/PD-L1 immunotherapy may respond to treatment without increased toxicity. Given the risk of graft rejection in solid organ transplant patients and also the potential for response, the role of anti-PD-1/PD-L1 immunotherapy needs to be carefully considered.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejca.2018.09.017

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 129

Metadata

Authors
Tio, M., Rai, R., Ezeoke, O. M., McQuade, J. L., Zimmer, L., Khoo, C., Park, J. J., Spain, L., Turajlic, S., Ardolino, L., Yip, D., Goldinger, S. M., Cohen, J. V., Millward, M., Atkinson, V., Kane, A. Y., Ascierto, P. A., Garbe, C., Gutzmer, R., Johnson, D. B., Rizvi, H. A., Joshua, A. M., Hellmann, M. D., Long, G. V., & Menzies, A. M.
Venue
European Journal of Cancer
Publisher
Elsevier BV
Published
2018-11
Volume
104
Pages
137-144
ISSN
0959-8049 (ISSN-L)
OpenAlex
W2897435840
Cited by
129
References
17
FWCI
5.56
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. https://app.cochat.ai/papers/10.1016/j.ejca.2018.09.017
The paper
Tio, M., Rai, R., Ezeoke, O. M., McQuade, J. L., Zimmer, L., Khoo, C., Park, J. J., Spain, L., Turajlic, S., Ardolino, L., Yip, D., Goldinger, S. M., Cohen, J. V., Millward, M., Atkinson, V., Kane, A. Y., Ascierto, P. A., Garbe, C., Gutzmer, R., . . . Menzies, A. M. (2018). Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2018.09.017

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.